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Abstract: In this study, thirteen sponge-derived terpenoids, including five linear 
furanoterpenes: furospinulosin-1 (1), furospinulosin-2 (2), furospongin-1 (3), furospongin-
4 (4), and demethylfurospongin-4 (5); four linear meroterpenes: 2-(hexaprenylmethyl)-2-
methylchromenol (6), 4-hydroxy-3-octaprenylbenzoic acid (7), 4-hydroxy-3-tetraprenyl-
phenylacetic acid (8), and heptaprenyl-p-quinol (9); a linear triterpene, squalene (10); two 
spongian-type diterpenes dorisenone D (11) and 11β-acetoxyspongi-12-en-16-one (12); a 
scalarane-type sesterterpene; 12-epi-deoxoscalarin (13), as well as an indole alkaloid, 
tryptophol (14) were screened for their in vitro activity against four parasitic protozoa; 
Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Leishmania donovani and 
Plasmodium falciparum. Cytotoxic potential of the compounds on mammalian cells was 
also assessed. All compounds were active against T. brucei rhodesiense, with compound 8 
being the most potent (IC50 0.60 μg/mL), whereas 9 and 12 were the most active 
compounds against T. cruzi, with IC50 values around 4 μg/mL. Compound 12 showed the 
strongest leishmanicidal activity (IC50 0.75 μg/mL), which was comparable to that of 
miltefosine (IC50 0.20 μg/mL). The best antiplasmodial effect was exerted by compound 11 
(IC50 0.43 μg/mL), followed by compounds 7, 10, and 12 with IC50 values around 1 μg/mL. 
Compounds 9, 11 and 12 exhibited, besides their antiprotozoal activity, also some 
cytotoxicity, whereas all other compounds had low or no cytotoxicity towards the 
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mammalian cell line. This is the first report of antiprotozoal activity of marine metabolites 
1–14, and points out the potential of marine sponges in discovery of new antiprotozoal lead 
compounds.  
 
Keywords: marine sponge; Spongia; Ircinia; antiprotozoal activity; Trypanosoma; 
Leishmania; Plasmodium 
 
1. Introduction  
 
It is estimated that over one billion people suffer from one or more tropical diseases. Among them, 
protozoal diseases caused by single-celled parasites are of particular importance. With the highest rates 
of complications and mortality, severe malaria, caused by the most fatal species Plasmodium 
falciparum, is the most dangerous protozoal disease. There were 247 million cases of malaria in 2006, 
causing nearly one million deaths, mostly among African children [1]. Key interventions to control 
malaria include prompt and effective treatment with artemisinin-based combination therapies (ACT), 
use of insecticide-treated nets by people at risk and indoor residual spraying with insecticide to control 
the vector, female Anopheles mosquitoes [2]. The resistance developed against safe insecticides and 
recent report of resistance against ACT in Southeast Asia [3], underlines the urgent need for novel 
chemotherapeutics against malaria. Apart from malaria, African trypanosomiasis, leishmaniasis and 
Chagas disease represent three most important diseases caused by parasitic protozoa. It is estimated 
that these three diseases are responsible for more than 110,000 deaths every year [4]. African 
trypanosomiasis (sleeping sickness) is caused by the parasitic flagellates; Trypanosoma brucei 
gambiense and T. brucei rhodesiense, which invade the central nervous system, leading to behavioral 
changes, coma, and ultimately, if left untreated, death [5]. Chagas' disease, or South American 
trypanosomiasis, is caused by T. cruzi and occurs primarily in young children. The intermediate host is 
a blood-sucking insect (triatome), which bites the victim and contaminates the wound with infected 
feces. Visceral leishmaniasis is another group of parasitic disease caused by Leishmania donovani, 
which is transmitted to humans by sand flies [6]. In the absence of a long-term protecting vaccine, the 
control of these parasitic infections is based on a few chemotherapeutic agents, most of which were 
discovered in the 1950s and whose mechanisms of action are not completely known. Furthermore, they 
are often associated with severe adverse effects and variable efficacy according to the phase of the 
disease. Also the emerging resistance against these drugs makes the discovery and development of 
new, safe and effective antiprotozoal agents an urgent need. 
The intensive research since 1970s has proved that marine organisms are magnificent sources of 
bioactive secondary metabolites. In some excellent reviews, a number of the compounds originating 
from marine organisms have been reported to possess in vitro and in vivo antiprotozoal activity [7–10]. 
In the continuation of our project concerning the evaluation of the anti-infective activity of Turkish 
marine organisms and their secondary metabolites [11], herein we report the broad-spectrum 
antiprotozoal activity and cytotoxicity of fourteen compounds, which we previously isolated from the 
marine sponges Spongia sp. and Ircinia sp. collected from the Turkish coastline of the Aegean Sea. 
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The majority of the compounds are terpenoids (Figure 1) and consist of five linear furanoterpenes: 
furospinulosin-1 (1), furospinulosin-2 (2), furospongin-1 (3), furospongin-4 (4), and 
demethylfurospongin-4 (5); four linear meroterpenes: 2-(hexaprenylmethyl)-2-methylchromenol (6), 
4-hydroxy-3-octaprenylbenzoic acid (7), 4-hydroxy-3-tetraprenylphenylacetic acid (8), and 
heptaprenyl-p-quinol (9); a linear triterpene, squalene (10); two spongian-type diterpenes: dorisenone 
D (11) and 11β-acetoxyspongi-12-en-16-one (12); a scalarane sesterterpene: 12-epi-deoxoscalarin 
(13), plus the indole alkaloid tryptophol (14). The metabolites were evaluated by medium-throughput 
screening methods for their in vitro activity against the mammalian stage of four parasitic protozoa; 
Trypanosoma brucei rhodesiense (bloodstream forms), Trypanosoma cruzi (intracellular amastigotes 
in L6 rat skeletal myoblasts), Leishmania donovani (axenic amastigotes), and Plasmodium falciparum 
(blood stage forms of K1 strain resistant to chloroquine and pyrimethamine). In order to assess the 
selectivity indices of the compounds, they were also tested towards a mammalian cell line (rat skeletal 
myoblasts: L6 cells). Melarsoprol, benznidazole, miltefosine, chloroquine and podophyllotoxin were 
used as reference drugs. This is the first study reporting the inhibitory effects of compounds 1–14 
against parasitic protozoa.  
 
Figure 1. Chemical structures of compounds 1–14. 
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2. Results and Discussion  
 
Marine sponge-originated compounds 1–14 showed very promising in vitro antiprotozoal activities. 
As shown in Table 1, all metabolites displayed some in vitro antitrypanosomal activity against T. b. 
rhodesiense with great variations in the IC50 values, which ranged from 0.60 μg/mL to 55.25 μg/mL. 
The best inhibition against this protozoan parasite was displayed by 4-hydroxy-3-
tetraprenylphenylacetic acid (8) (IC50 0.60 μg/mL), followed by dorisenone D (11, IC50 2.47 μg/mL), 
heptaprenyl-p-quinol (9, IC50 3.54 μg/mL), 11β-acetoxyspongi-12-en-16-one (12, IC50 4.14 μg/mL), 
demethylfurospongin-4 (5) (IC50 4.90 μg/mL) and tryptophol (14, IC50 5.89 μg/mL). On the other 
hand, the best-inhibiting compounds towards T. cruzi were found to be heptaprenyl-p-quinol (9, IC50 
4.08 μg/mL), and 11β-acetoxyspongi-12-en-16-one (12, IC50 4.51 μg/mL). Only three of the remaining 
compounds, 3, 13 and 14, showed anti-Trypanosoma cruzi activity with higher IC50 values. 
Trypanocidal activity profile of furospongin-1 (3) and 12-epi-deoxoscalarin (13) against both 
Trypanosoma species was almost identical. However, tryptophol (14), the only non-terpenoid marine 
natural product tested, was 8-fold less activite against T. cruzi (IC50 49.37 μg/mL) than against T. b. 
rhodesiense. The majority of the metabolites also showed growth inhibitory activity against L. 
donovani. Among all active substances, 11β-acetoxyspongi-12-en-16-one (12) exerted a highly 
remarkable inhibition against L. donovani with an IC50 value of 0.75 μg/mL, which was comparable to 
that of the reference compound, miltefosine (IC50 0.20 μg/mL). Furospongin-1 (3) and 4-hydroxy-3-
octaprenylbenzoic acid (7) also displayed notable antileishmanial activity with IC50 values of 4.80 and 
5.60 μg/mL, respectively, whereas the remaining active compounds had moderate IC50 values ranging 
from 9.60 μg/mL to 18.9 μg/mL. Except for 2-(hexaprenylmethyl)-2-methylchromenol (6) and 
heptaprenyl-p-quinol (9), all metabolites screened in this study displayed some antiplasmodial activity 
against the multi-drug resistant strain of P. falciparum (Table 1). The best inhibition was exhibited by 
dorisenone D (11, IC50 0.43 μg/mL). Also 11β-acetoxyspongi-12-en-16-one (12), squalene (10), and  
4-hydroxy-3-octaprenylbenzoic acid (7) showed significant activity with IC50 values of 1.09,  
1.16 and 1.57 μg/mL, respectively. The IC50 values of the remaining eight active metabolites were in a 
narrower range and varied between 3.30 μg/mL and 14.02 μg/mL. From the evaluation of the 
metabolites against mammalian L6 cells, some interesting results became apparent. As shown in  
Table 1, the IC50 values of compounds 9, 11 and 12 against mammalian cells were very similar to their 
IC50 values against the parasitic protozoa. Although there are variations in the antiprotozoal activity 
against different protozoa of interest, the toxicity against mammalian cells might still indicate a lack of 
selective toxicity, i.e. general toxicity, for these compounds. However, the most potent trypanocidal 
compound, 4-hydroxy-3-tetraprenylphenylacetic acid (8) was devoid of any cytotoxicity even at the 
highest test concentrations (90 μg/mL). The remaining compounds had either low or no cytotoxic 
potential (IC50 > 90 μg/mL).  
Protozoal diseases continue to be one of the major health problems worldwide and since protozoa 
develop resistance quickly to currently available drug series, the discovery of novel antiprotozoal 
agents has become a pressing need. A number of chemically diverse phytochemicals (e.g., alkaloids, 
terpenes, quinones, flavonoids, aurones, xanthones, and cyclic tetrapeptides) with antiprotozoal 
activity have been reported in the literature [12,13]. Several types of marine natural products, such as 
manzamine alkaloids, plakortin type acetogenins and cyano/isocyano/formamide containing sesqui- 
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and diterpenes have been studied in vitro and/or in vivo for antiprotozoal (mostly antimalarial) activity 
[8–10], but the real potential of marine organisms has remained largely uninvestigated. Hence, this 
study aimed at focusing on the in vitro antiprotozoal activity of a variety of sponge terpenoids, 
including di-, sester-, and triterpenes, as well as various length of polyterpenes and meroterpenes, 
which were never tested against any of the protozoa of interest. This study is a part of a large screening 
campaign we have recently initiated on marine extracts/metabolites and has already yielded some 
promising compounds as shown in this study.  
 
Table 1. In vitro antiprotozoal and cytotoxic activities of sponge-derived compounds 1–14. 
The IC50 values are in μg/mL and represent the average of at least two independent assays 
performed in duplicates.  
Compound 
Trypanosoma b. 
rhodesiense 
Trypanosoma 
cruzi 
Leishmania 
donovani  
Plasmodium 
falciparum 
Cytotoxicity  
1 27.45 >90 14.2 11.18 >90 
2 16.16 >90 >90 3.51 34.0 
3 13.94 17.49 4.80 14.02 27.45 
4 17.94 >90 >90 7.51 >90 
5 4.90 >90 10.2 13.36 >90 
6 41.43 >90 15.9 >20 >90 
7 13.11 >90 5.60 1.57 86.48 
8 0.60 >90 >90 3.30 >90 
9 3.54 4.08 18.9 >20 2.62 
10 15.03 >90 >90 1.16 34.89 
11 2.47 >90 >90 0.43 3.93 
12 4.14 4.51 0.75 1.09 3.32 
13 55.25 40.43 >90 7.48 60.33 
14 5.89 49.37 9.60 5.08 63.46 
Standards 0.003a 0.359b 0.20c 0.056d 0.004e 
Reference compounds a: melarsoprol, b: benznidazole, c: miltefosine, d: chloroquine, e: podophyllotoxin. 
 
Linear furanoterpenes 1–5 studied here showed a moderate to good, but generally broad-spectrum 
growth inhibitory activity against almost all parasites and were devoid of significant cytotoxicity. Anti-
infective activity of several linear furanoterpenes is known [14], but to our knowledge, their 
antiparasitic activity has not been explored in detail. Compounds 1 and 2 are structurally very similar, 
except that 2 contains an additional isoprene unit. The length of isoprene chain appears to have an 
impact on antiparasitic potentials of linear furanoterpenes, as 2 shows better T. b. rhodesiense and P. 
falciparum activity, but fails to inhibit L. donovani cultures. Again the presence of an additional 
isoprene unit, as in the case of 2, leads to some cytotoxicity. There were also some differences in the 
antiprotozoal potential of furanoterpenes 4 and 5, which differ from each other by the presence of a 
terminal methyl group. Interestingly, furospongin-1 (3), a C-21 furanoterpene with two furane rings 
and a hydroxyl function is active against all parasite strains and bears some cytotoxicity.  
Meroterpene-derivatives (6–9) had also significant levels of biological activity on the parasitic 
protozoa tested. In several previous studies, some meroterpene-type compounds were reported to have 
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antimalarial activity in μM range [15–17], which is consistent with the results obtained in the present 
study. 4-Hydroxy-3-tetraprenylphenylacetic acid (8) has emerged as the most potent compound against 
African trypanosomes without any cytotoxicity. Interestingly, a related compound, heptaprenyl-p-
quinol (9), arrested the growth of African and American trypanosomes equipotently with moderate 
IC50 values. However, 9 also inhibited the growth of mammalian cells, indicating a narrow therapeutic 
window. Some sponge-derived quinol derivatives have been reported to exert cytotoxic activity 
[18,19], the mechanism of which has been associated with the oxidation of quinol to quinone. The 
meroterpenes 7–9 have structural similarities in their linearity, however it is obvious that the presence 
of a shorter isoprenyl chain and a phenylacetic acid as a terminal unit, as found in compound 8, is most 
favored for T. b. rhodesiense activity and highest selectivity. The linear triterpene squalene (10) 
appeared to have good antiplasmodial activity, plus some moderate activity against T. brucei 
rhodesiense. To our knowledge, squalene has never been reported to exhibit antiplasmodial or 
antitrypanosomal activity up to date.  
Spongian diterpenoids are natural products isolated mainly from sponges and nudibranchs, which 
feed on these sponges [20]. It has been speculated that the oxygenated positions of spongian-
diterpenoids act as a complexing moiety for cations and such complexation might play a role in their 
biological activity [21]. The spongian diterpene dorisenone D (11) was found to be the best 
antiplasmodial agent with some efficacy against T. brucei rhodesiense. For an antimalarial hit, the 
WHO Special Program for Research and Training in Tropical Diseases (TDR) defines an activity 
criterion to have an IC50 value < 0.2 μg/mL [22]. In our study, dorisenone D (11) emerged to be the 
closest one to this criterion. Towards the malaria parasite, dorisenone D (11) has a selectivity index of 
>9 (calculated by: IC50 against L6 cells/IC50 against parasite). If the cytotoxicity of 11 can be lowered 
by medicinal chemistry approach, dorisenone D could become a promising antiplasmodial lead 
compound. The second spongian diterpene 11β-acetoxyspongi-12-en-16-one (12) exhibited the highest 
antileishmanial potential, however, its selectivity index for L. donovani was very low (4.4). It was also 
toxic towards all other parasites, pointing out rather a general toxicity. Compound 12 is the 7-deacetyl 
derivative of 11, however there are very significant differences in their antiparasitic activity. As shown 
in Table 1, it seems that the absence of an acetoxy function at C-7 position, as in 12, is favored for 
particularly for T. cruzi and L. donovani activity. Notably, both compounds show almost identical 
cytotoxicity towards mammalian cells, which might suggest that other shared structural characteristics 
are responsible for cytotoxicity. Plasmodium falciparum was the most susceptible parasite for 12-epi-
deoxoscalarin (13), the only scalaran-terpene investigated herein.  
Many indole-derivatives from natural sources have been reported with antiprotozoal activity  
[23–26]. Tryptophol (3-indole ethanol) (14), a plant auxin derivative, which was also isolated from a 
marine sponge for the first time by our group [27], showed a broad-spectrum activity versus T. brucei 
rhodesiense, L. donovani and P. falciparum without eliciting high cytotoxicity.  
 
3. Experimental Section  
 
3.1. Isolation of compounds 1–14 
 
Compounds 1–14 were isolated from the marine sponges Spongia sp. and Ircinia sp. collected from 
the Turkish coastline of the Aegean Sea using various chromatographic techniques as described 
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previously and characterized by means of spectroscopic techniques [27,28]. The purity of compounds 
(>95%) was confirmed by 1H- and 13C-NMR.  
 
3.2. Activity against Plasmodium falciparum  
 
In vitro activity against erythrocytic stages of P. falciparum was determined by a modified  
[3H]-hypoxanthine incorporation assay [29], using the chloroquine- and pyrimethamine-resistant K1 
strain and the standard drug artemisinin. Briefly, parasite cultures incubated in RPMI 1640 medium 
with 5% Albumax (without hypoxanthine) were exposed to serial drug dilutions in microtiter plates. 
After 48 h of incubation at 37°C in a reduced oxygen atmosphere, 0.5 μCi 3H-hypoxanthine was added 
to each well. Cultures were incubated for a further 24 h before they were harvested onto glass-fiber 
filters and washed with distilled water. The radioactivity was counted using a BetaplateTM liquid 
scintillation counter (Wallac, Zurich). The results were recorded as counts per minute (CPM) per well 
at each drug concentration and expressed as percentage of the untreated controls. IC50 values were 
calculated from the sigmoidal inhibition curves using Microsoft Excel. Chloroquine was the reference 
drug used. 
 
3.3. Activity against Trypanosoma brucei rhodesiense 
 
Trypanosoma brucei rhodesiense, STIB 900 strain, and the standard drug, melarsoprol, were used 
for the assay. This stock was isolated in 1982 from a human patient in Tanzania and after several 
mouse passages cloned and adapted to axenic culture conditions. Minimum Essential Medium (50 µL) 
supplemented with 25 mM HEPES, 1g/L additional glucose, 1% MEM non-essential amino acids 
(100x), 0.2 mM 2-mercaptoethanol, 1 mM Na-pyruvate and 15% heat inactivated horse serum was 
added to each well of a 96-well microtiter plate [30,31]. Serial drug dilutions of seven 3-fold dilution 
steps covering a range from 90 to 0.123 μg/mL were prepared. Then 104 bloodstream forms of T. b. 
rhodesiense STIB 900 in 50 µL was added to each well and the plate incubated at 37 °C under a 5% 
CO2 atmosphere for 72 h. 10 µL Alamar Blue (resazurin, 12.5 mg in 100 mL double-distilled water) 
was then added to each well and incubation continued for a further 2–4 h [32]. Then, the plates were 
read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, 
Sunnyvale, CA, USA) using an excitation wavelength of 536 nm and an emission wavelength of 588 
nm. Data were analyzed using the microplate reader software Softmax Pro (Molecular Devices 
Cooperation, Sunnyvale, CA, USA). 
 
3.4. Activity against Trypanosoma cruzi  
 
Rat skeletal myoblasts (L6 cells) were seeded in 96-well microtitre plates at 2000 cells/well in  
100 μL RPMI 1640 medium with 10% FBS and 2 mM L-glutamine. After 24 h the medium was 
removed and replaced by 100 μL per well containing 5000 trypomastigote forms of T. cruzi Tulahuen 
strain C2C4 containing the β-galactosidase (Lac Z) gene [33]. After 48 h, the medium was removed 
from the wells and replaced by 100 μL fresh medium with or without a serial drug dilution of seven  
3-fold dilution steps covering a range from 90 to 0.123 μg/mL. After 96 h of incubation, the plates 
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were inspected under an inverted microscope to assure growth of the controls and sterility. Then, the 
substrate CPRG/Nonidet (50 μL) was added to all wells. A color reaction developed within 2–6 h and 
could be read photometrically at 540 nm. Data were transferred into the graphic programme Softmax 
Pro (Molecular Devices), which calculated IC50 values. Benznidazole was the reference drug used. 
 
3.5. Activity against Leishmania donovani  
 
Amastigotes of L. donovani strain MHOM/ET/67/L82 were grown in axenic culture at 37 °C in SM 
medium at pH 5.4 supplemented with 10% heat-inactivated fetal bovine serum under an atmosphere of 
5% CO2 in air. One hundred microlitres of culture medium with 105 amastigotes from axenic culture 
with or without a serial drug dilution were seeded in 96-well microtitre plates. Serial drug dilutions 
covering a range from 90 to 0.123 μg/mL were prepared. After 72 h of incubation the plates were 
inspected under an inverted microscope to assure growth of the controls and sterile conditions. 10 μL 
of Alamar Blue (12.5 mg resazurin dissolved in 100 mL distilled water) [34] were then added to each 
well and the plates incubated for another 2 h. Then, the plates were read with a Spectramax Gemini XS 
microplate fluorometer using an excitation wavelength of 536 nm and an emission wavelength of 588 
nm. Data were analyzed using the software Softmax Pro (Molecular Devices Cooperation, Sunnyvale, 
CA, USA). Decrease of fluorescence (=inhibition) was expressed as percentage of the fluorescence of 
control cultures and plotted against the drug concentrations. From the sigmoidal inhibition curves the 
IC50 values were calculated. Miltefosine was used as reference drug. 
 
3.6. Cytotoxicity against L6 cells  
 
Assays were performed in 96-well microtiter plates, each well containing 100 μL of RPMI 1640 
medium supplemented with 1% L-glutamine (200 mM) and 10% fetal bovine serum, and 4 × 104 L6 
cells (a primary cell line derived from rat skeletal myoblasts). Serial drug dilutions of seven 3-fold 
dilution steps covering a range from 90 to 0.123 μg/mL were prepared. After 72 h of incubation, the 
plates were inspected under an inverted microscope to assure growth of the controls and sterile 
conditions. Ten μL of Alamar Blue solution was then added to each well and the plates incubated for 
another 2 h. Then the plates were read with a Spectramax Gemini XS microplate fluorometer using an 
excitation wavelength of 536 nm and an emission wavelength of 588 nm. Data were analysed using the 
microplate reader software Softmax Pro. Podophyllotoxin was the reference drug used. 
 
4. Conclusions  
 
This is the first report of antiprotozal activity assessments of fourteen sponge metabolites. The 
results demonstrate that some of the compounds, such as 4-hydroxy-3-tetraprenylphenylacetic acid (8), 
can be considered as an interesting hit against parasitic diseases. Besides 8, dorisenone D (11) and 
11β-acetoxyspongi-12-en-16-one (12) may also be seen as hits, after their selectivity is increased by 
rational drug design process. Further investigations may include the assessment of underlying 
mechanisms of action of these compounds and evaluation of their in vivo efficacy in animal models, 
which could not be performed in the current study due to low available amounts of the compounds. 
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